Cargando…

The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease

Alzheimer’s disease (AD) is a chronic disabling disease that affects the central nervous system. The main consequences of AD include the decline of cognitive functions and language disorders. One of the causes leading to AD is the decrease of neurotransmitter acetylcholine (ACh) levels in the brain,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vecchio, Immacolata, Sorrentino, Luca, Paoletti, Annamaria, Marra, Rosario, Arbitrio, Mariamena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267037/ https://www.ncbi.nlm.nih.gov/pubmed/34285627 http://dx.doi.org/10.1177/11795735211029113

Ejemplares similares

Language impairment in Alzheimer’s disease and benefits of acetylcholinesterase inhibitors
por: Ferris, Steven H, et al.
Publicado: (2013)

Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis
por: Walczak-Nowicka, Łucja Justyna, et al.
Publicado: (2021)

New Acetylcholinesterase Inhibitors for Alzheimer's Disease
por: Mehta, Mona, et al.
Publicado: (2012)

Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer’s Disease: Are Irreversible Inhibitors the Future?
por: Moss, Donald E.
Publicado: (2020)

Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer’s Disease. Review of Reviews
por: Moreta, Marta Pérez-Gómez, et al.
Publicado: (2021)

Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer’s Disease
por: Son, Minky, et al.
Publicado: (2019)

Efficacy of Souvenaid(®) Combined with Acetylcholinesterase Inhibitors in the Treatment of Mild Alzheimer’s Disease
por: García-Alberca, José María, et al.
Publicado: (2023)

Cardiovascular Complications of Acetylcholinesterase Inhibitors in Patients with Alzheimer’s Disease: A Narrative Review
por: Young, Sara, et al.
Publicado: (2021)

Novel Acetylcholinesterase Inhibitors Based on Uracil Moiety for Possible Treatment of Alzheimer Disease
por: Semenov, Vyacheslav E., et al.
Publicado: (2020)

Molecular docking analysis of acetylcholinesterase inhibitors for Alzheimer's disease management
por: Hakeem, Israa J
Publicado: (2023)

Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer’s disease
por: Zou, Dajiang, et al.
Publicado: (2023)

FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer’s disease
por: Paroni, Giulia, et al.
Publicado: (2014)

Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy
por: dos Santos, Thaiane Coelho, et al.
Publicado: (2018)

Intranasal administration of acetylcholinesterase inhibitors
por: Costantino, Henry R, et al.
Publicado: (2008)

Acetylcholinesterase inhibitor modifications: a promising strategy to delay the progression of Alzheimer's disease
por: Bhattacharya, Soumee, et al.
Publicado: (2015)

Discovery of new acetylcholinesterase inhibitors for Alzheimer’s disease: virtual screening and in vitro characterisation
por: David, Benoit, et al.
Publicado: (2021)

Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer’s Disease and Parkinson’s Dementia: Systematic Review and Meta-Analysis
por: Bittner, Nadine, et al.
Publicado: (2023)

Nanomedicine in the Management of Alzheimer’s Disease: State-of-the-Art
por: Mir Najib Ullah, Shehla Nasar, et al.
Publicado: (2023)

Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer’s Disease Therapy
por: Arya, Ashwani, et al.
Publicado: (2021)

Inhibitors of Acetylcholinesterase and Butyrylcholinesterase Meet Immunity
por: Pohanka, Miroslav
Publicado: (2014)

N-Acetylcholinesterase-Induced Apoptosis in Alzheimer's Disease
por: Toiber, Debra, et al.
Publicado: (2008)

Mouse models of multiple myeloma: technologic platforms and perspectives
por: Rossi, Marco, et al.
Publicado: (2018)

Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats
por: Di Martino, Maria Teresa, et al.
Publicado: (2020)

Imidazopyranotacrines as Non-Hepatotoxic, Selective Acetylcholinesterase Inhibitors, and Antioxidant Agents for Alzheimer′s Disease Therapy
por: Boulebd, Houssem, et al.
Publicado: (2016)

Design, Synthesis, and Evaluation of Acetylcholinesterase and Butyrylcholinesterase Dual-Target Inhibitors against Alzheimer’s Diseases
por: Guo, Yan, et al.
Publicado: (2020)

Acetylcholinesterase inhibitors and cognitive stimulation, combined and alone, in treating individuals with mild Alzheimer’s disease
por: Devita, Maria, et al.
Publicado: (2021)

Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives
por: Arbitrio, Mariamena, et al.
Publicado: (2018)

7-Methoxytacrine-p-Anisidine Hybrids as Novel Dual Binding Site Acetylcholinesterase Inhibitors for Alzheimer’s Disease Treatment
por: Korabecny, Jan, et al.
Publicado: (2015)

White matter hyperintensities in cholinergic pathways may predict poorer responsiveness to acetylcholinesterase inhibitor treatment for Alzheimer’s disease
por: Lee, Li-Hua, et al.
Publicado: (2023)

Development of a Pharmacogenetic Lab-on-Chip Assay Based on the In-Check Technology to Screen for Genetic Variations Associated to Adverse Drug Reactions to Common Chemotherapeutic Agents
por: Iemmolo, Rosario, et al.
Publicado: (2020)

Comedication and Treatment Length in Users of Acetylcholinesterase Inhibitors
por: Sverdrup Efjestad, Anne, et al.
Publicado: (2017)

A Novel Application of Multiscale Entropy in Electroencephalography to Predict the Efficacy of Acetylcholinesterase Inhibitor in Alzheimer's Disease
por: Tsai, Ping-Huang, et al.
Publicado: (2015)

Development of p-Tau Differentiated Cell Model of Alzheimer’s Disease to Screen Novel Acetylcholinesterase Inhibitors
por: Uras, Giuseppe, et al.
Publicado: (2022)

Altered Levels of Acetylcholinesterase in Alzheimer Plasma
por: García-Ayllón, María-Salud, et al.
Publicado: (2010)

Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and β-amyloid inhibitors for Alzheimer’s disease
por: Yusufzai, Samina Khan, et al.
Publicado: (2018)

BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?
por: Tagliaferri, Pierosandro, et al.
Publicado: (2009)

Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice
por: Arbitrio, Mariamena, et al.
Publicado: (2020)

Acetylcholinesterase inhibitors attenuate angiogenesis
por: Miyazaki, Ryohei, et al.
Publicado: (2012)

Acetylcholinesterase Inhibitors: Pharmacology and Toxicology
por: Čolović, Mirjana B, et al.
Publicado: (2013)

Heterologous Amyloid Seeding: Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease
por: Jean, Létitia, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_6envvtsolgagdg9st7pdneb5vi